Using disease-modifying therapies in MS tends to reduce the risk of stroke, though effects vary depending on the type of DMT, ...

The FDA added a boxed warning about rare cases of anaphylaxis associated with the multiple sclerosis (MS) drug glatiramer acetate (Copaxone, Glatopa), the agency announced on Wednesday.

Zydus’ generic Glatiramer Acetate Injection is an FDA-approved, AP-rated substitutable generics of Copaxone ® 20 mg/ml, 40 mg/ml and indicated for the treatment of relapsing forms of Multiple ...

Most of the patients in these reported cases experienced anaphylaxis within 1 hour after injection. Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and ...

Copaxone and its generic form, Glatopa, may lead to anaphylaxis even in patients who’ve been taking the medication for months without incident. The FDA warns that the injectable MS drugs ...

Please provide your email address to receive an email when new articles are posted on . The FDA has advised health care professionals and patients with multiple sclerosis that treatment with ...

Along with the fine, the long-running investigation has concluded that Teva used a "web" of patents to illegally block lower-cost generic versions of Copaxone (glatiramer acetate), whose last ...

Glatiramer acetate (Copaxone) is an injectable drug that treats relapsing forms of multiple sclerosis in adults. It’s a man-made version of a protein similar to one found in myelin, an ...

82 cases of anaphylaxis reported globally from 1996 to 2024, including six fatalities. New Boxed Warning added to highlight the risk of severe allergic reactions at any stage of treatment.

Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes Zydus Lifesciences Limited ...